Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A.
Lepper ER, et al.
Clin Cancer Res. 2005 Oct 15;11(20):7398-404. doi: 10.1158/1078-0432.CCR-05-0520.
Clin Cancer Res. 2005.
PMID: 16243813
Clinical Trial.